Cantor Fitzgerald L. P. Purchases New Shares in Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• Cantor Fitzgerald acquired a new stake of 68,890 Teva shares in Q3 (about $1.39M), while institutional investors now own roughly 54.05% of the company.
• Several brokerages raised price targets—most notably Goldman Sachs to $45, Bank of America to $32 and Piper Sandler to $41—leaving a MarketBeat average target of $37.67 and a "Moderate Buy" consensus.
• Teva beat expectations in the latest quarter with EPS $0.96 vs. $0.65 and revenue $4.71B vs. $4.36B, and set FY2026 guidance of $2.570–$2.770 EPS.

Cantor Fitzgerald L. P. acquired a new stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 68,890 shares of the company's stock, valued at approximately $1,392,000.

Other large investors have also modified their holdings of the company. Howard Bailey Securities LLC increased its stake in shares of Teva Pharmaceutical Industries by 3.5% in the 3rd quarter. Howard Bailey Securities LLC now owns 14,451 shares of the company's stock valued at $292,000 after purchasing an additional 494 shares in the last quarter. ASR Vermogensbeheer N.V. raised its holdings in Teva Pharmaceutical Industries by 1.6% in the 3rd quarter. ASR Vermogensbeheer N.V. now owns 31,915 shares of the company's stock worth $645,000 after purchasing an additional 515 shares during the period. CIBC Private Wealth Group LLC boosted its position in Teva Pharmaceutical Industries by 15.5% during the third quarter. CIBC Private Wealth Group LLC now owns 4,020 shares of the company's stock worth $81,000 after purchasing an additional 540 shares in the last quarter. Retirement Planning Co of New England Inc. boosted its position in Teva Pharmaceutical Industries by 1.8% during the third quarter. Retirement Planning Co of New England Inc. now owns 33,230 shares of the company's stock worth $671,000 after purchasing an additional 588 shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its holdings in Teva Pharmaceutical Industries by 0.5% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 118,209 shares of the company's stock valued at $1,981,000 after purchasing an additional 615 shares during the period. Institutional investors and hedge funds own 54.05% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on TEVA. Bank of America upped their target price on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a "buy" rating in a research note on Tuesday, December 9th. The Goldman Sachs Group lifted their price target on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a "buy" rating in a research note on Monday, February 9th. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a report on Saturday, January 31st. Piper Sandler restated an "overweight" rating and set a $41.00 price objective (up from $40.00) on shares of Teva Pharmaceutical Industries in a research report on Wednesday, March 4th. Finally, Scotiabank increased their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a "sector outperform" rating in a report on Thursday, January 29th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Teva Pharmaceutical Industries presently has an average rating of "Moderate Buy" and an average target price of $37.67.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, insider Eric A. Hughes sold 9,533 shares of the stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $31.67, for a total value of $301,910.11. Following the completion of the sale, the insider directly owned 107,711 shares in the company, valued at $3,411,207.37. This represents a 8.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Brian Savage sold 1,127 shares of the firm's stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $31.67, for a total transaction of $35,692.09. Following the completion of the transaction, the insider directly owned 10,914 shares in the company, valued at approximately $345,646.38. This represents a 9.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 858,799 shares of company stock valued at $28,185,035. 0.49% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $29.60 on Thursday. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.04 and a quick ratio of 0.80. The stock's 50 day simple moving average is $32.78 and its 200-day simple moving average is $26.92. The company has a market cap of $34.04 billion, a PE ratio of 24.67, a price-to-earnings-growth ratio of 10.07 and a beta of 0.72. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, beating the consensus estimate of $0.65 by $0.31. The firm had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The firm's revenue was up 11.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, equities research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.